Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin | Zendy

Nakai Ritsuko | Zendy; Fukuhara Suguru | Zendy; Maeshima Akiko Miyagi | Zendy; Kim SungWon | Zendy; Ito Yuta | Zendy; Hatta Shunsuke | Zendy; Suzuki Tomotaka | Zendy; Yuda Sayako | Zendy; Makita Shinichi | Zendy; Munakata Wataru | Zendy; Suzuki Tatsuya | Zendy; Maruyama Dai | Zendy; Izutsu Koji | Zendy

Open Access

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin

Author(s) -

Nakai Ritsuko,

Fukuhara Suguru,

Maeshima Akiko Miyagi,

Kim SungWon,

Ito Yuta,

Hatta Shunsuke,

Suzuki Tomotaka,

Yuda Sayako,

Makita Shinichi,

Munakata Wataru,

Suzuki Tatsuya,

Maruyama Dai,

Izutsu Koji

Publication year - 2019

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.2543

Subject(s) - alectinib , medicine , brentuximab vedotin , anaplastic large cell lymphoma , anaplastic lymphoma kinase , refractory (planetary science) , chemotherapy , lymphoma , oncology , transplantation , autologous stem cell transplantation , cancer research , cd30 , physics , astrobiology , malignant pleural effusion , lung cancer

This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research